Company intelligence / Profile preview

Walk Vascular

Irvine, California, United States

Ownership: Private
Development stage: Other

Overview

Walk Vascular commercialized JETi peripheral thrombectomy systems for minimally invasive mechanical removal of peripheral blood clots. The systems received FDA 510(k) clearance and CE Mark approval, are in use, and are supported by real-world clinical results, including a registry enrolling up to 250 patients in the US and Europe. Early studies showed high efficacy, with 92% thrombus reduction and technical success in 76% of procedures[1][2][3][5]. The company was acquired by Abbott in September 2021.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Proximo Medical (commercialization partner, prior to acquisition)[4]

Beyond the preview

Go deeper on Walk Vascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Walk Vascular.

Explore the full profile